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Summary 
Recombinant monocyte chemotactic-activating factor (MCAF) has been shown to induce histamine 
release from human basophils with  a dose response between 10 -9 and 10 -6 M.  The peak of 
activity was reached at  10 -7 M.  Histamine release by MCAF was rapid with an initial rate 
comparable with histamine release by an optimal dose of anti-IgE. MCAF led to peak histamine 
release within 1 min. 80% of the subjects tested were responsive to MCAF or anti-IgE, while 
all were responsive to FMLP.  The percentage histamine release by MCAF was, however, less 
than that seen with anti-IgE or FMLP, but this was attributable to a lesser percent release in 
nonatopic subjects;  atopic subjects responded similarly to all three agonists. MCAF was also 
shown to activate highly purified human basophils more readily than mixed leukocytes, and its 
activity was inhibited by a polyclonal rabbit antibody. At a suboptimal concentration (2.5  x 
10-9 M), MCAF was unable to prime the basophil to histamine release by other secretagogues. 
However, interleukin 3 (I1:3) and I1:5 could each prime basophils for MCAF-induced secretion. 
Therefore, our results suggest that MCAF may be a major contributor to the histamine-releasing 
activity seen in peripheral blood mononuclear cell supernatants that has been designated histamine 
releasing factor(s). 
W 
e  have  characterized  histamine-releasing  factors 
(HRF) 1 from PBMC and platelets,  and a number of 
cytokine-like molecules have been shown to influence hista- 
mine release from human basophils (1). Low concentrations 
of I1:1, I1:3,  I1:5, and GM-CSF can prime human basophils 
to cause augmented release of histamine and/or leukotriene 
C4 upon incubation with anti-IgE, C5a, or C3a (2, 3). IL-3 
and GM-CSF, at higher concentrations, can directly release 
histamine from some donors, most of whom are atopic (4, 
5). However, previous studies have demonstrated that the factor 
responsible for the major activity in PBMC supernatant is 
different from any of these cytokines (4,  6). 
Purification of HRF from stimulated PBMC and platelet 
supernatants reveals three separate peaks of histamine-releasing 
activity that do not correspond to aforementioned cytokines 
and have apparent molecular masses of 8-10, 15-17, and 35-41 
kD (7). Further characterization of the 8-10-kD material re- 
1 Abbreviations  used in  this paper."  CTAP III, connective tissue-activating 
peptide III; HKF, histamine-releasing factor; MCAF, monocyte chemotactic- 
activating  factor;  NAP-2,  neutrophil-activating  peptide 2. 
vealed one active component to be connective tissue-activating 
peptide III (CTAP III) and its derivative neutrophil-activating 
peptide 2 (NAP-2) (8), which are derived from platelet basic 
protein. Cytokines resembling these proteins in physicochem- 
ical properties (size and sequence homology) include mono- 
cyte-derived neutrophil chemotactic factor, or IL-8 (9), and 
monocyte chemotactic-activating factor (MCAF) (10, 11). I1:8 
has  been  demonstrated  to  inhibit  histamine release  from 
basophils by partially purified HRF,  II:3,  and CTAP III/ 
NAP-2 (12), and as such, is likely the histamine release in- 
hibitory factor (HRIF) described previously (13). Here we 
report that the human recombinant MCAF causes histamine 
release from basophils,  and is the most potent cytokine-like 
agonist thus far described. 
Materials and Methods 
Materials.  Chemicals used in the histamine and leukotriene re- 
lease experiments and mediators assays were purchased as previ- 
ously described (7). Human rlL-3 (sp act, 10  s U/mg) and riD5 (sp 
act,  106  U/rag)  (Amgen  Biologicals, Thousand  Oaks,  CA), 
anti-human  Leu-M3 (CD14), anti-Leu-Sb (CD2),  anti-Leu-16 
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goat anti-mouse IgG antibody (Jackson ImmunoResearch  Labora- 
tories, Inc., West Grove, PA), affinity-purified  goat anti-human 
IgE antibody (Kirkegaard  & Perry Laboratories  Inc., Gaithersburg, 
MD), recombinant human MCAF, with maximal chemotactic ac- 
tivity on human monocytes at 20 ng/ml (pepro Tech Inc., Rocky 
Hill, NJ), Percoll (Pharmacia, Uppsala, Sweden), human recom- 
binant C5a, FMLP, and bacitracin (Sigma Chemical Co., St. Louis, 
MO) were used. The CSa had activity  similar  to serum-derived  C5a. 
Basophil Donors.  Donors were recruited from laboratory and 
hospital personnel. Allergic subjects had of a history of rhinitis, 
rhinoconjunctivitis, or asthma, and positive skin tests to common 
aeroallergens. Normal  subjects were skin test-negative healthy 
persons with negative personal or family history of any allergic 
disease. All allergic subjects were off medications for at least 3 d 
before blood was drawn. The protocol for blood donation was ap- 
proved by the human subjects committee (SUNY-Stony Brook). 
Cell Preparation.  The procedure for leukocyte  isolation has been 
described in detail (14). In some experiments  basophils  were purified 
from peripheral blood on Percoll gradients according to Leonard 
et al. (15), followed  by negative panning selection as described (16) 
using anti-Leu-5b, anti-Leu-16, and anti-Leu-M3 mAbs. The pan- 
ning yielded basophils of >85%  purity. The average recovery of 
basophils in six donors studied was 20%. 
Histamine Release  from Basophils.  Aliquots of 15 #1 of MCAF, 
anti-IgE, or FMLP were incubated with 135/zl of prewarmed leu- 
kocytes or basophil suspension at 37~  for 45 rain. Total hista- 
mine in basophils was released by heating in a boiling water bath. 
Histamine release experiments were done in duplicate and results 
expressed as the percentage released. Spontaneous  release was <5% 
and was subtracted  from the calculated  histamine  release. The radio- 
enzymatic assay  for histamine was performed in duplicate for each 
sample according to Beaven et al. (17). 
Anti-MCAF Antibody Preparation.  Rabbit antiserum to MCAF 
(kindly provided by Dr. Christine Burns, Advanced Magnetics, 
Boston, MA) and normal rabbit serum were made 45% in ammo- 
nium sulfate, centrifuged at 10,000 g for 5 min, the supernatant 
was discarded, and the precipitate was dissolved in PBS and dia- 
lyzed against PBS. A 1:800 dilution of the rabbit antiserum in- 
hibited monocyte chemotaxis induced by 2.5  x  10 -9 M MCAF 
by 50%. 
StatisticaIAnalysis.  Results are presented as mean _+ SEM, and 
the statistical analysis  was performed with Wilcoxon's signed rank 
test or Student's t test, using StatWorks (Cricket Software,  Philadel- 
phia, PA). 
Results 
Characteristics of MCAF-induced Histamine Release.  We ini- 
tially determined the release of histamine from the basophils 
of six subjects with 10 -11 to 10 -6 M MCAF. As shown in 
Fig.  1, MCAF released a significant percent of histamine at 
concentrations of 10 -9 M and above, with a maximal effect 
at ~  M. The curve appeared  to plateau between 10 -7 
and 10-6  M.  The kinetics of histamine release by MCAF 
was extremely rapid with the peak release observed  within 
the first minute with no further increment between 1 min 
and 1 h.  Thus, histamine release by MCAF is among the 
most rapidly acting basophil secretagognes thus far described 
and resembles C5a and FMLP (18, 19). We also determined 
that MCAF requires divalent cations for its effect. When the 
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Figure 1.  Dose-dependent  histamine  release by MCAE Basophils  of six 
individuals  were challenged  with MCAF  from 10- ~ to 10-6 M, and the 
percentage histamine  release was determined. Results are expressed as a 
mean percentage of histamine  release _+ SEM. *p *g 0.022; "*p *i 0.014 
vs. histamine  release induced by 10-u M MCAF (Wilcoxon's  rank sum 
test). 
dose-response  experiment (Fig.  1) was performed in the ab- 
sence of calcium and magnesium, there was no histamine re- 
lease. It appears that MCAF-mediated histamine release from 
basophils is a secretory,  noncytolytic process. 
We next enlarged the population studied to better appreciate 
donor responsiveness to MCAF and included atopic and non- 
atopic subjects. Leukocytes from 31 subjects were tested for 
histamine  release  due  to  MCAF  (10 -7  M),  anti-IgE  (1 
#g/ml), and FMLP (10-s M). There were 13 atopic subjects 
and 18 nonatopic subjects.  MCAF caused histamine release 
in 25 of 31 donors, anti-IgE released histamine in 26 of 31 
donors, and FMLP released histamine in all subjects tested. 
The nonresponders to MCAF were not the same subjects who 
did not respond to anti-IgE. The histamine release by MCAF 
(29  _+  3.3%) was significantly less than that by anti-IgE or 
FMLP, which were 44.9  +  4.6% and 44.5  +  2.8%, respec- 
tively. When the subjects were sorted into atopics and non- 
atopics,  nonresponders to MCAF included two atopics and 
four nonatopics, while nonresponders to anti-IgE included 
two atopics  and three nonatopics. The percentage of hista- 
mine release upon stimulation with MCAF in atopics vs. non- 
atopics was 35  +  5.7 and 27  +  4.3, respectively,  and this 
difference was not statistically significant (p > 0.05 student's 
t test). When the responses to MCAF, anti-IgE, and FMLP 
were compared in atopic subjects only, there was no significant 
difference among the three. However, MCAF caused less hista- 
mine release in the nonatopic group (27  +_  4.3% vs. anti- 
IgE at 41.8  _+  5.9%; p <  0.042, Wilcoxon's rank sum test) 
or FMLP (43.6  _+  3.3%; p <  0.007, Wilcoxon's rank sum 
test). Thus, the difference seen in all 31 subjects was reflected 
by the lesser response  to MCAF in the nonatopic group. 
Comparison of  Histamine Release in Mixed Leukocytes vs. Highly 
PurifiedBasophils.  Basophils from six separate subjects were 
isolated as described in Materials and Methods to 85-90% 
purity, and histamine release to MCAF (10-; M) and anti- 
IgE (50 ng/ml) was compared with the release seen with mixed 
leukocytes (1-2% basophils).  As seen in Fig. 2, MCAF and 
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Figure 2.  Comparison  of  the histamine release from dextran-sedimented 
leukocytes with highly purified basophils by MCAF (10-7 M) and anti- 
IgE (0.05/zg/ml). The cells were challenged with each agonist for 45 min 
at 37~  Each  bar represents the mean +_ SEM of  six experiments in different 
donors. *Release  with MCAF was significantly  greater when the purified 
basophils were compared with mixed leukocytes (p g  0.023 Wilcoxon's 
rank sum test). 
anti-IgE  released histamine  from purified basophils as well 
as mixed leukocytes. Given the rapidity of histamine release 
from mixed leucocytes (<1 min) and substantial release from 
purified basophils,  the likelihood of another cell-derived in- 
termediate is extremely low.  The augmented histamine re- 
lease from purified basophils seen with MCAF is unexplained, 
but  may relate to its  known interactions  with  monocytes, 
which would lessen its effective concentration in mixed leu- 
kocyte preparations. 
Inhibition  of MCAF Histamine-releasing Activity  by Anti- 
MCAF Antibody.  MCAF at  10 -7 M  was incubated with 
either control or anti-MCAF rabbit antibody for I h at 37~ 
The mixture was microfuged at 10,000 g for 3 min, and the 





Z  2o 
"~  15 
~  s 
MCAF  MCAF+anti-MCAF  MCAF+Control Ab 
Figure 3.  Effect  of  anti-MCAF rabbit antibody on MCAF-induced  hista- 
mine release. MCAF (10 -v M) was preincubated with rabbit anti-human 
MCAF antibody or with rabbit control antibody at dilution 1:20 for 60 
min at 37~  The mixture was spun for 3 min at 10,000  g, and the super- 
natant was assayed for histamine release. The results of six experiments 
in different donors are shown. Each bar represents the mean _+ SEM. *p 
0.014 vs. MCAF  +  anti-MCAF (Wilcoxoffs rank sum test). 
supernatant added to the leukocytes of six donors, and hista- 
mine release determined.  As seen in Fig. 3, the anti-MCAF 
inhibited histamine release by 50%  while the control anti- 
body had  no effect. 
IL3 and 11.,5 Prime Basophils to MCAF-induced Histamine 
Release.  Prior studies have indicated that IL-3, IL-5, and GM- 
CSF are capable of priming basophils for histamine release 
due to anti-IgE, CSa, and II:8 (3). In this study, we wished 
to corroborate these data and test  whether MCAF can act 
as a primer at low concentrations  or whether  secretion by 
MCAF can be primed by the other cytokines. Basophils were 
preincubated with either buffer, IL-5, IL-3, or MCAF as shown 
in Table 1 for 10 min at 37~  and then challenged with ei- 
ther buffer, anti-IgE, FMLP,  C5a,  IL-5, IL-3, or MCAF as 
potential secretagogues. The low percent release of 8.8% with 
anti-IgE alone reflects the low concentration (50 ng/ml) used, 
Table  1.  Effect of Priming Basophils with IL-5, IL-3, or MCAF upon Histamine Release Induced by a Variety of Secretagogues 
Percent  of histamine release 
Buffer  anti-IgE  FMLP  C5a  IL-5  IL-3  MCAF 
Buffer  2.2  •  0.7  8.8  •  3.5  53  •  7.3  39  _+  6.4  6.6  •  1.2  6.1  •  0.8  16.3  _+  6.8 
IL-5  6.2  _+  0.9  30.1  •  7.4*  72.7  •  8.8"  68  _+  8.4*  -  12  _+  6.2  35  •  6* 
I1-3  7.3  •  1.4  32.2  •  7.5*  74  •  8.7*  66.3  •  8.2*  11.1  •  1.8  -  36.5  •  6.3" 
MCAF  17.1  •  6.2  26.9  _+  8.8  66.3  •  11.3  55.2  _+  9.5  24.9  •  9  24.5  _+  7.2  - 
Leukocytes of six separate donors were preincubated in buffer or with cytokines IL-5 (100 ng/ml),  IL-3 (5,000 U/ml), MCAF (20 ng/ml)  for 10 
rain, and further challenged for 35 min with anti-IgE (0.05/zg/ml),  FMLP (10 -s M), CSa (10 -s M), IL-5 (100 ng/ml),  IL-3 (5,000 U/ml), and 
MCAF (20 ng/ml). The mean  _+  SEM of histamine release is shown. 
* Statistically significant augmentation of release (p <  0.05) as a result of preincubation with either IL-5 or IL-3. 
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lease of 6.6 and 6.1% for IL-5 and IL-3 is considered border- 
line. Substantial release is seen with FMLP, C5a, and MCAF 
when tested alone with values of 53  __  7.3, 39  _+  6.4, and 
16.3  _+  6.8%,  respectively. Preincubation with either IL-5 
or I1.-3 significantly enhanced the percent histamine release 
with all four secretagogues, but IL-5 and IL-3 did not prime 
each other.  When  MCAF was used as the primer  (2.5  x 
10 -9 M), the sum of its release (17.1%) plus that seen with 
anti-IgE  (8.8%),  FMLP (53.7%),  and C5a (37.6%)  alone 
are equal to that seen in the sequential additional experiment, 
thus,  no priming  effect was evident.  MCAF therefore ap- 
pears to be a releasing agent and not a primer.  Its activity 
as a secretagogue, however, can be primed by either IL-3 or IL-5. 
Discussion 
MCAF  belongs  to  the  proinflammatory  "intercrine" 
cytokine family. It has been purified as a 15-kD factor from 
LPS-stimulated myelomonocyte cell line THP-1 and from cul- 
tured supernatants  of PHA-stimulated human  PBMC (10, 
11). The amino  acid sequence of MCAF has  20-55%  ho- 
mology with other members of intercrine family, including 
RANTES, IL-8, GRO/MGSA, PF-4, CTAP III, and its de- 
rivatives 3-thromboglobulin  and NAP-2 (20).  MCAF is a 
potent chemoattractant  for monocytes but not for neutro- 
phils or lymphocytes, and it activates monocyte superoxide 
anion production  and release  of lysosomal enzymes in the 
presence of cytochalasin B  (21). 
We have demonstrated that some members of this group 
of inflammatory mediators release histamine from basophils 
and contribute to the histamine-releasing activity present in 
supernatants of PBMC and platelets (8, 22). IL-8, for example, 
is a weak agonist and can stimulate histamine release at con- 
centrations  >10 -6 M  (23).  However,  at  lower concentra- 
tions, IL-8 functions as a histamine release inhibitory factor 
(12). CTAP III and NAP-2 are also weak agonists for hista- 
mine release on a molar basis (peak activity,  10 -6 to 10 -s M); 
however, these proteins are so abundant in platelet releasate 
that they can contribute significantly to the histamine-releasing 
activity found in the 8-kD fraction of stimulated superna- 
rants (22). We have now investigated the histamine-releasing 
capability of MCAF and demonstrate that it is the most po- 
tent cytokine-like secretagogue hitherto described. It acts as 
an agonist for basophils of most subjects irrespective of al- 
lergic status, and is active at concentrations  as low as 10-9 
M  with peak activity at  10-7 M. The magnitude  of hista- 
mine release by MCAF can be augmented if the cells are primed 
by Ib3 or II~5.  However, MCAF does not act as a primer 
for other agonists. Histamine release from human basophils 
is most likely due to direct interaction  of MCAF with the 
surface of basophils rather than via another cell-derived in- 
termediate, but we have not performed binding experiments 
in the present  studies.  We infer the presence of a receptor 
because the release is extremely rapid, and is augmented when 
highly purified basophils are compared with mixed leukocytes. 
Histamine releasing factors (HRF) are thought to contribute 
significantly to the protracted histamine release and basophil 
and/or mast cell degranulation seen in a wide variety of im- 
munologic disorders, including late phase allergic reactions 
(1), chronic urticaria (24), atopic dermatitis (25), asthma (26, 
27), and rheumatoid arthritis (28). The specific contribution 
of MCAF to histamine release in such disorders is the subject 
of ongoing investigations, and its relationship to the purified 
components derived from mononuclear cell supernatants re- 
quires further  definition. 
Address correspondence to Allen P. Kaplan, Department  of Medicine, SUNY-Stony Brook, HSC T-16, 
Stony Brook,  NY 11794. 
Received for publication 8  October 1991 and in revised  form  31  October 1991. 
R.~rences 
1.  Kaplan, A.P., S. Reddigari, M. Baeza, and P. Kuna. 1991. Hista- 
mine releasing factors and cytokine-dependent  activation of 
basophils and mast cells. Adv. Immunol. 50:237. 
2.  Bishoff, S.C., A.L. De Weck, and C.A. Dahinden.  1990. In- 
terleukin  3 and granulocyte/macrophage-colony-stimulating 
factor render human basophil responsive to low concentration 
of complement  component C3a. Proc. Natl. Acad. Sci. USA. 
87:6813. 
3.  Bischoff, S.C., T. Brunner, A.L. De Weck, and C.A. Dahinden. 
1990. Interleukin 5 modifies histamine release and leukotriene 
generation by human basophils in response to diverse agonist. 
J. Exp. Med. 172:1577. 
4.  HaakoFrendscho,  M., N. Arai, K.-I. Arai, M.L. Baeza, A. Finn, 
and  A.P. Kaplan. 1988. Human  recombinant  granulocyte- 
macrophage colony-stimulating factor and interleukin 3 cause 
basophil histamine release. J.  Clin. Invest. 82:17. 
5.  MacDonald, S.M., R.P. Schleimer, A. Kagey-Soboka,  S. Gillis, 
and L.M. Lichtenstein. 1989. Recombinant IL-3 induces hista- 
mine release from human  basophils. J. Immunol. 142:3527. 
6.  Alam, R., J.B. Welter, P.A. Forsythe, M.A. Lett-Brown, and 
J.A. Grant. 1989. Comparative effect of recombinant Ibl, -2, 
-3, -4, and -6, IFN-gamma,  granulocyte macrophage-colony- 
stimulating  factor, tumor necrosis factor-alfa, and histamine 
releasing factors on the secretion of histamine from basophils. 
J. Immunol. 142:3431. 
7.  Baeza, M.L.,  S.R. Reddigari,  M. Haak-Frendscho, and A.P. 
492  Monocyte  Chemotactic and Activating Factor Releases Histamine Kaplan.  1989. Purification and  further characterization of 
human mononuclear cell histamine releasing factor.J. Clin. In- 
vest. 83:1204. 
8.  Baeza, M.L., S.R. Reddigari, D. Kornfeld, N. Ramani, E.M. 
Smith, P.A. Hossler, T. Fischer, C.W. Castor, P.G. Gorevic, 
and A.P. Kaplan. 1990. Relationship of one form of human 
histamine  releasing  factor  to connective  tissue  activating  peptide- 
III. J.  Clin.  Invest. 85:1516. 
9.  Matsushima, K., K. Morishita, T. Yoshimura, S.  Lavu, Y. 
Kobayashi, W. Lew,  E. Appella, H.F. Kung, E.J. Leonard, and 
J.J. Oppenheim. 1988. Molecular cloning of a human mono- 
cyte-derived  neutrophil chemotactic factor (MDNCF) and the 
induction of MDNCF mRNA by interleukin 1 and tumor 
necrosis factor, j.  Exp.  Med.  167:1883. 
10.  Yoshimura,  T., E.A. Robinson, S. Tanaka, E. Appella, and E.J. 
Leonard. 1989. Purification and amino acid analysis of two 
monocyte chemoattractants produced by phytohemagglutinin- 
stimulated human blood mononuclear leukocytes.J, lmmunol. 
142:1956. 
11.  Matsushima, K., C.G. Larsen, G.C. DuBois, and J.J. Oppen- 
heim. 1989. Purification and characterization of a novel  mono- 
cyte chemotactic and activating factor produced by a human 
myelomonocytic cell line.  j. Exit  Med.  169:1485. 
12.  Kuna, P., S.R. Reddigari, D. Kornfeld, and A.P. Kaplan. 1991. 
IL-8 inhibits histamine release from human basophils induced 
by histamine releasing  factors, connective  tissue activating pep- 
tide III, and IL-3.  J. Immunol.  147:1920. 
13.  Alam,  R.,  J.A.  Grant,  and  M.A.  Lett-Brown.  1988. 
Identification of a histamine releasing inhibitory factor pro- 
duced by human mononuclear cells in vitro, f  Clin.  Invest. 
82:2056. 
14.  Kaplan, A.P., M. Haak-Frendscho,  A. Fauci, C. Dinarello, and 
E. Halbert. 1985. A histamine-releasing  factor from activated 
human mononuclear cells,  j.  Immunol.  135:2027. 
15.  Leonard, E.J., R.L. Roberts, and A. Skeel. 1984. Purification 
of human blood basophils by single step isopycnic  banding on 
percoll. J. Leukocyte Biol. 35:169. 
16.  Wysocki, L.J., and V.L. Sato. 1978. "Panning" for lympho- 
cytes: A method for cell selection. Proc. Natl. Acad. Sci. USA. 
75:2844. 
17.  Beaven, M.A.,  A. Jacobsen, and Z. Horakova. 1972. Mod- 
ification of an enzymatic isotopic assay of histamine and its 
application to measurement of histamine in tissues, serum, and 
urine. Clin.  Chem.  Acta.  37:91. 
18.  Grant,J.A., E. Dupree, A.S. Goldman, D.R. Schultz, and A.L. 
Jackson. 1975. Complement-mediated  release of histamine  from 
human leukocytes,  f  Immunol.  114:1101. 
19.  Siraganian, R.P., and W.A. Hook. 1977. Mechanism of hista- 
mine release by formyl methionine containing peptide.  J. Im- 
munol.  119:2078. 
20.  Oppenheim, J.J., C.O.C. Zacharie, N. Mukaida, and K. Mat- 
sushima. 1991. Properties of the novel proinflammatory su- 
pergene "lntercrine"  cytokine family. Annu.  Rev. Immunol. 
9:617. 
21.  Zachariae, C.O.C., A.O. Anderson, H.L. Thompson, E. Ap- 
pella, A. Mantovani, J.J. Oppenheim, and K. Matsushima. 
1990. Properties of monocyte chemotactic  and activating  factor 
(MCAF) purified from a human fibrosarcoma  cell line..]. Exp. 
Med.  171:2177. 
22.  Reddigari, S.R., P. Kuna, G. Miragliotta, D. Kornfeld, C.W. 
Castor, and A.P. Kaplan. 1991. Connective Tissue Activating 
Peptide-III and Neutrophil Activating Peptide-2 both release 
histamine from human basophils, j.  Allergy Clin.  Immunol. 
87:241. (Abstr.) 
23.  White, M.V., T. Yoshimura,  W. Hook, M.A. Kaliner,  and E.J. 
Leonard.  1989. Neutrophil  attractantActivation  protein-1 
(NAP-l) causes human basophil histamine release. Immunol. 
Lett.  22:151. 
24.  Elias,  J., E. Boss, and A.P. Kaplan. 1986. Studies of the cd- 
lular infiltrate of chronic idiopathic urticaria: Prominence of 
T-lymphocytes,  monocytes, and mast cells.J. Allergy Clin. Im- 
munol. 78:914. 
25.  Sampson, H.A., K.R. Broadbent, andJ. Bernhisel-Broadbent. 
1989. Spontaneous release of histamine from basophils and 
histamine-releasing factor in patients with atopic dermatitis 
and food hypersensitivity. N. Engl. J. Med.  321:228. 
26.  Alam, R., P. Kuna, J. Rozniecki, and B. Kuzminska. 1987. 
The  magnitude  of  spontaneous  production  of histamine 
releasing factor (HRF) by lymphocytes  in vitro correlates with 
the state of  bronchial hyperreactivity in patients with asthma. 
J. Allergy Clin.  Immunol.  79:103. 
27.  Kuna, P., R. Alam, B. Kuzminska, and J. Rozniecki. 1989. 
The effect of preseasonal immunotherapy on the production 
of histamine releasing factor (HRF) by mononuclear cells from 
patients with seasonal  asthma: results of  a double  blind placebo- 
controlled, randomized study../. Allergy Clin. Immunol. 83:816. 
28.  Gruber, B., M. Poznansky, E. Boss,  J. Partin, P. Gorevic, and 
A.P. Kaplan. 1986. Characterization and functional studies of 
rheumatoid synovial mast cells: Activation by secretagogues, 
anti-IgE, and histamine-releasing  lymphokine.  Artkritis Rheum. 
29:944. 
493  Kuna et al. 